Puma Biotechnology Inc - Company Profile
Powered by 
All the data and insights you need on Puma Biotechnology Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Puma Biotechnology Inc Strategy Report
- Understand Puma Biotechnology Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Puma Biotechnology Inc (Puma) is a biopharmaceutical company that develops and commercializes cancer care products. The company focuses on in-licensing drug candidates that have already completed initial clinical trials and seek to further develop drug candidates for the treatment of various forms of cancer. The company operates through one reportable business segment that develops and commercializes products to enhance cancer care. Currently, the company primarily focused on the development and commercialization of Nerlynx, oral version of neratinib, its advanced drug candidates intended for the treatment of HER2-positive breast cancer and HER2 mutated cancers.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company’s R&D activities focus on development of new products and enhancement of existing products. The company conducts research to advance its product candidates to address various cancer indications. In FY2022, the company expenses were US$59.2 million in its R&D activities, which was 25.9% of its revenue and declined 17.5%YoY. It comprises of 21 granted patents and four pending patent applications in the US under its agreement with Pfizer.
Business Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer